Health
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
PRINCETON, N.J., July 18, 2025--BMS Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/fb290b453d9099415599acb1c7d8c830"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/P2QTocfPmi9v1IrIxmX6Lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fb290b453d9099415599acb1c7d8c830","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eOEJsyjaA0JGAmUt5A.HPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/fb290b453d9099415599acb1c7d8c830","width":1200,"height":165}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., July 18, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674). Patients saw a numerical and clinically meaningful improvement in RBC transfusion independence favoring Reblozyl, in line with previous results from the Phase 2 trial (NCT03194542).","length":691,"tagName":"p"},{"type":"text","content":"Several important secondary measures also showed a clinically meaningful benefit favoring Reblozyl, which included a higher number of patients who achieved at least a 50% reduction (and by at least 4 RBC units) in RBC transfusion burden, as well as a higher number of patients achieving a hemoglobin (Hb) level increase by at least 1 g/dL while remaining transfusion independent for at least 12 consecutive weeks.","length":413,"tagName":"p"},{"type":"text","content":"Frequently observed treatment emergent adverse events were consistent with the known safety profile of Reblozyl previously reported across indications.","length":151,"tagName":"p"},{"type":"text","content":"The company is encouraged by the clinically meaningful results of the study and will engage with the FDA and EMA to discuss the submission of marketing applications.","length":165,"tagName":"p"},{"type":...